What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a

On June 22, 2026, Orbimed Advisors, a 10% Owner of Enliven Therapeutics, Inc. (NASDAQ:ELVN), disclosed the indirect sale of 860,123 shares for a total transaction value of approximately $39.0 million, as reported in the SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average purchase price ($45.36); post-transaction value based on June 22, 2026 market close.

What is the structure of Orbimed's ownership post-transaction?Following this transaction, all remaining 6,555,102 shares reported in the filing are held indirectly through OrbiMed Genesis Master Fund, L.P. and OrbiMed Private Investments VII, LP.

What proportion of total holdings was impacted by this transaction?The sale represented 11.60% of Advisors Llc Orbimed's total indirect holdings prior to the transaction, reflecting a meaningful reduction in its aggregate ownership but not a full exit.

How does current trading context relate to the transaction price?The shares were sold at around $45.36 per share, while the stock closed at $45.96 on June 22, 2026, and subsequently increased to $50 as of June 26, 2026, indicating a modest appreciation post-sale.

* 1-year performance calculated using June 22nd, 202

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/know-orbimeds-39-million-enliven-162312437.html)